China Shenghuo Pharmaceutical Holdings, Inc. (KUN) said Friday that its audited consolidated financial statements for the fiscal year ended December 31, 2011, included in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2012 contained a going concern qualification from its independent registered public accounting firm, Marcum Bernstein & Pinchuk LLP.
China Shenghuo is mainly engaged in the research, development, manufacture, and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty State Food and Drug Administration approved medicines, including the flagship product Xuesaitong Soft Capsules.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.